Joseph
O'Neill, the gay former director of the Office of
National AIDS Policy at the White House, has been
named chief executive officer and president of Immune
Response Corp., a biopharmaceutical company focusing
on HIV and multiple sclerosis research. O'Neill, who
succeeds John N. Bonfiglio at Immune Response, helped
craft the 2003 President's Emergency Plan for
AIDS Relief, a $15 billion global initiative to combat the
AIDS epidemic.
Immune Response
had developed an experimental HIV vaccine called Remune
that was hoped to prevent HIV infection but was shown in a
November 2000 study to be ineffective. The vaccine is
currently being studied to see if adding it to an
antiretroviral drug cocktail enhances the
medications' anti-HIV activity. The company
also is developing IR103, an immune-based therapy to
treat HIV, and NeuroVax, an immune-based treatment for MS.
(Advocate.com)